I'm looking for

Our Mission & Our Vision

Our mission is to prevent and treat gynecologic cancers with equity, thereby improving lives through advocacy, engagement, education, research and collaboration.

Our vision is to eradicate gynecologic cancers.

 

Core Values

  • Advocacy: Advance policies that promote the eradication of gynecologic cancer.
  • Collaboration: Support and promote partnerships to advance the care of women with or at risk for gynecologic cancers.
  • Diversity & Inclusion: Commit to cultural humility and diversity of thought and engagement.
  • Education: Provide innovative education and continuous learning.
  • Engagement: Provide opportunities to participate in the progress of the gynecologic oncology profession.
  • Leadership & Professionalism: Set an example of integrity, quality and excellence.
  • Patient Care: Foster empathetic, comprehensive and high-value care to improve the lives of women with or at risk for gynecologic cancer.
  • Research: Advance innovation and discovery to eradicate gynecologic cancer.

2021-2024 Strategic Goals and Supporting Initiatives

1. Advance the prevention, early diagnosis, and treatment of gynecologic Cancers by establishing and promoting standards of excellence.

  • Develop clinical statements and recommendations regarding the care and prevention of gynecologic cancers.
  • Integrate standards in the development of educational programs and publications.
  • Increase awareness of SGO resources to the global healthcare community.
  • Diversify dissemination strategies to increase access and adoption in clinical practice.
  • Advocate more equitable care across all patient populations.

2. Foster greater diversity, equity, inclusion, and accountability within the Society
and the larger healthcare community to improve health outcomes for all patients.

  • Attract, diversify, and develop future generations of healthcare professionals and stakeholders who treat and care for gynecologic cancer patients.
  • Increase diversity within membership and volunteer leadership roles.
  • Increase participation in content development from a diverse group of professionals.
  • Identify and support research and education aimed at improving health outcomes for diverse patient populations.

3. Support the membership through operational excellence, innovation, engagement, and efficiency.

  • Create, customize, and deliver timely, relevant and accessible content, information, and education.
  • Develop a diverse portfolio of high-quality, innovative programs, products, and services that support the professional development and wellness of members.
  • Invest in enabling capabilities including people and technology.
  • Build greater connectivity among members to cultivate relationships, knowledge sharing and mentoring.

Join SGO Today

What you get out of membership changes your patient’s lives. What you give from your membership changes the world. Join your community today.

Become a Member

Evening ISS: Transforming Gynecologic Cancer Treatment with Antibody-Drug Conjugates: Best Practices for Integrating Novel Therapies, Addressing Adverse Events, and Optimizing Multidisciplinary Collaboration

Supporting company: Med Learning Group 

Friday, March 14 | 7:00-8:30 p.m. PT | Room 606-609

Faculty: Bradley J. Monk, MD, FACS, FACOG and Ursula A. Matulonis, MD 

Antibody-drug conjugates (ADCs) are an important advancement in the treatment of cancer. We are pleased to present an informative satellite symposium designed to equip you with information and skills needed to optimally use ADCs for your patients with advanced gynecologic cancers. This program will use an interactive format that includes didactic presentations, case presentations, and discussion sessions, along with audience response technology. Renowned experts will review the latest evidence and clinical guidelines related to ADCs for women’s cancers and share their perspectives and guidance on incorporating these agents into practice, including individualized treatment planning and multidisciplinary toxicity monitoring and management. 

  • Describe the mechanisms of action of antibody-drug conjugates (ADCs) and the rationale for their use in gynecologic cancers 
  • Develop personalized strategies for incorporating ADCs into the treatment of patients with advanced gynecologic cancers 
  • Assess and manage adverse events associated with administration of ADCs in gynecologic cancers 

Register Today

 

ISS I: Exploring the Horizons in Endometrial Cancer: Biomarkers, Guidelines, and Coordinated Care

Supporting company: Medscape LLC

Saturday, March 15 | 7:00-8:15 a.m. | Room: 6AB

Faculty: Mansoor Raza Mirza, MD; Ramez N. Eskander, MD; and Ritu Salani, MD, MBA 

Recognizing that caring for patients with advanced endometrial cancer is a journey that must be appropriately mapped out, Medscape Oncology presents a 90-minute educational session to serve as a road map to the optimal path of care. A group of 3 world-renowned gynecologic oncologists will guide learners through the options and their choices at the different destinations. 

  • Increased knowledge regarding the rationale for immunotherapy in advanced endometrial cancer. 
  • Greater competence related to tailoring treatment based on standard-of-care practices for a patient with primary advanced endometrial cancer.  
  • Selecting the most optimal treatment option for a patient with recurrent advanced endometrial cancer.  
  • Managing adverse events associated therapies used to treat advanced endometrial cancer.  
  • Greater confidence in their ability to incorporate a multidisciplinary practice into treatment to optimize patient outcomes. 

Register Today

 

ISS II: A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs

Supporting company: PeerView

Saturday, March 15 | 7:00-8:15 a.m. PT | Room 6E

Moderator: Kathleen N. Moore, MD, MS

Faculty: David M. O’Malley, MD and Bhavana Pothuri, MD, MS 

  • Gain insights into cutting-edge treatments for advanced ovarian cancer including PARP inhibitors, ADCs, and immunotherapy approaches 
  • Explore the most recent efficacy and safety data, along with practical guidance on integrating modern therapies into clinical practice 
  • Acquire actionable, team-based approaches to identify, mitigate, and manage treatment-related adverse events for improved patient care 

Register Today

 

ISS III: Cases from the Community: Investigators Discuss the Optimal Clinical Care of Patients with HER2-Positive Gynecologic Cancers

Supporting company: Research to Practice  

Saturday, March 15 | 12:30-2:00 p.m. PT | Room: 6AB

Moderator: David M O’Malley, MD 

Faculty: Kathleen N. Moore, MD, MS and Alessandro D. Santin, MD 

Module 1: Strategies to Identify Patients with HER2-Positive Gynecologic Cancers 

  • Incidence of HER2 expression documented among various gynecologic cancer subtypes 
  • Definition of HER2 positivity in the pivotal DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) 
  • Appropriate integration of HER2 immunohistochemistry testing into routine gynecologic oncology practice 
  • Potential utility of other testing methods, such as next-generation sequencing and liquid biopsy, to identify patients with advanced gynecologic cancers who might benefit from HER2-targeted therapy 
  • Optimal source material for and timing of HER2 testing for advanced gynecologic cancers 

Module 2: Available Data with and Practical Application of HER2-Targeted Therapy for Advanced Gynecologic Cancers 

  • Published research studies with HER2-targeted strategies, such as trastuzumab and pertuzumab/trastuzumab, for advanced endometrial cancer 
  • Limited clinical trial database surrounding the use of HER2-targeted therapy for other advanced gynecologic cancers 
  • Key efficacy outcomes achieved with T-DXd among patients with advanced ovarian, endometrial and cervical cancers in the DESTINY-PanTumor02 study 
  • Recent FDA approval of T-DXd for pretreated HER2-positive solid tumors; implications for the management of advanced gynecologic cancers 
  • Other novel agents and strategies under evaluation for patients with HER2-positive gynecologic cancers 

Module 3: Identification and Management of Adverse Events (AEs) with T-DXd 

  • Spectrum and incidence of common (eg, gastrointestinal [GI] toxicities, myelosuppression) and more serious (eg, interstitial lung disease [ILD], cardiac toxicities) treatment-emergent AEs observed with T-DXd 
  • Recommendations for monitoring and immediate reporting of symptoms of ILD with T-DXd 
  • Strategies to manage T-DXd-associated ILD; indications for restarting T-DXd after resolution of symptoms 
  • Appropriate monitoring of complete blood counts and left ventricular ejection fraction during therapy with T-DXd 
  • Recommended algorithms for mitigating and managing cardiac toxicities, cytopenias, GI side effects and other complications of T-DXd 
  • Initial dosing of T-DXd and dose-modification strategies for patients with treatment-related toxicities 

Register Today

 

ISS IV: Expert Panel Discussion: Maintenance Therapy in Advanced Ovarian Cancer – Results from Key Clinical Trials 

Supporting company: AstraZeneca   

Saturday, March 15 | 12:30-2:00 p.m. PT | Room: 6E

Faculty: Thomas Kirvack, MD; Cecelia Boardman, MD; and Thomas Herzog, MD

Join Drs. Krivak, Herzog, and Boardman for an interactive trivia-style presentation as they delve into key clinical trials and share their real-world insights on maintenance therapy in advanced ovarian cancer. Throughout the session, you’ll have the opportunity to participate in trivia questions designed to challenge and expand your knowledge of the subject. 

 

ISS V: Building a Comprehensive Treatment Pathway in Ovarian Cancer

Supporting company: Medscape Education

Sunday, March 16 | 7:00-8:15 a.m. PT | Room 6AB

Faculty: Bradley J. Monk, MD, FACS, FACOG; Ursula A. Matulonis, MD; and Domenica Lorusso, MD, PhD 

The pathways of care in advanced ovarian cancer have become increasingly complicated with the addition of numerous therapies and biomarkers that guide treatment decisions. Join us in Seattle as top ovarian cancer experts draw a roadmap to care based on real-world patient case scenarios, including the role of biomarkers in the treatment decision-making process, selection of first-line therapeutic regimens, management of treatment-related adverse events, and other practical considerations. Don’t miss your opportunity to interact with the experts! 

 

ISS VI: Expanding the Arsenal: Innovative Strategies to Treat Platinum Resistant Ovarian Cancer

Supporting company: Corcept Therapeutics

Sunday, March 16 | 7:00-8:15 a.m. PT | Room 6E

Moderator: Thomas J. Herzog, MD 

Faculty: Nicoletta Colombo, MD, PhD; Alexander B. Olawaiye, MD; and Lyndsay Willmott, MD

This symposium will focus on the latest advancements in the treatment of advanced, platinum-resistant high-grade epithelial ovarian cancer.  Ovarian cancer remains a significant challenge in oncology, particularly for heavily pretreated patients. This symposium aims to provide critical insights into the efficacy of new treatment options beyond antibody drug conjugates (ADCs). This session will provide a comprehensive overview discussing the competitive landscape, treatment outcomes, and learning about new innovative therapies beyond ADCs.

ISS VII: WHAT CLINICIANS WANT TO KNOW: Addressing Current Questions and Controversies in the Management of Patients with Ovarian Cancer

Supporting company: Research to Practice 

Sunday March, 16 | 12:30-2:00 p.m. PT | Room 6AB

Moderator: Angeles Alvarez Secord, MD, MHSc

Faculty: Kathleen N Moore, MD, MS; Ritu Salani, MD, MBA; and Shannon N Westin, MD, MPH, FASCO, FACOG

Module 1: Up-Front Treatment for Advanced Ovarian Cancer (OC)

  • Optimal approaches to biomarker testing for patients with newly diagnosed advanced OC; significance of somatic and germline BRCA mutations and homologous recombination deficiency status for treatment decision-making
  • Long-term data with olaparib, niraparib and olaparib/bevacizumab maintenance therapy for patients with newly diagnosed OC; factors affecting selection among these strategies
  • Early findings with niraparib/bevacizumab maintenance after front-line platinum-based chemotherapy/bevacizumab; ongoing evaluation and potential clinical role
  • Biological rationale for combining PARP inhibitors with anti-PD-1/PD-L1 antibodies with or without bevacizumab for OC
  • Major efficacy and safety findings from the Phase III DUO-O study of up-front durvalumab in combination with chemotherapy and bevacizumab followed by durvalumab, bevacizumab and olaparib as maintenance therapy
  • Other ongoing Phase III research efforts evaluating PARP inhibitors in combination with immune checkpoint inhibitors for advanced OC; anticipated completion dates

Module 2: Management of Relapsed/Refractory OC

  • Long-term follow-up from pivotal trials evaluating PARP inhibitors for platinum-sensitive and platinum-resistant recurrent OC; implications of updated indications for these agents in relapsed disease
  • Clinical utility, if any, of rechallenge with a PARP inhibitor for patients who have experienced disease progression on or after prior PARP inhibitor therapy
  • Incidence and clinical relevance of folate receptor alpha (FRα)-positive OC; optimal approaches to and timing of FRα testing
  • Available efficacy and safety data, including findings from the Phase III MIRASOL trial, with mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant OC
  • Available findings from the Phase II PICCOLO trial of mirvetuximab soravtansine for FRα-positive, platinum-sensitiveOC; ongoing Phase III evaluation and potential clinical role in this setting
  • Optimal integration of mirvetuximab soravtansine into OC management algorithms
  • Prevalence of HER2 overexpression in advanced OC; outcomes achieved with trastuzumab deruxtecan (T-DXd) among patients with advanced HER2-positive OC in the DESTINY-PanTumor02 study
  • Recent FDA approval of T-DXd for pretreated HER2-positive solid tumors; implications for OC management
  • Module 3: Novel Investigational Therapies for Advanced OC
  • Frequency of CDH6 expression in OC; mechanism of antitumor activity of the novel CDH6-directed antibody-drug conjugate raludotatug deruxtecan (R-DXd)
  • Early research findings with R-DXd for patients with heavily pretreated platinum-resistant advanced OC
  • Ongoing evaluation of R-DXd for platinum-resistant advanced OC in the Phase II/III REJOICE-Ovarian01 trial
  • Mechanism of action of the novel engineered cytokine nemvaleukin alfa
  • Activity and safety observed with nemvaleukin alfa in combination with pembrolizumab in the platinum-resistant OC cohort of the Phase I/II ARTISTRY-1 study
  • Design, eligibility criteria and primary and secondary endpoints of the Phase III ARTISTRY-7 trial of nemvaleukin alfa/pembrolizumab versus chemotherapy for platinum-resistant advanced OC; estimated completion date
  • Other novel agents and strategies under evaluation for the treatment of advanced OC

Module 4: Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC

  • Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors in patients with OC
  • Reported risk of long-term serious side effects, such as acute myeloid leukemia and myelodysplastic syndromes, with PARP inhibitor therapy
  • Initial dosing of approved PARP inhibitors and appropriate dose-modification strategies for patients experiencing treatment-related toxicity
  • Pathogenesis and incidence of ocular adverse reactions associated with mirvetuximab soravtansine, such as visual impairment, keratopathy, dry eye, photophobia, eye pain and uveitis
  • Recommended approaches to monitoring for, preventing and ameliorating mirvetuximab soravtansine-associated ocular toxicities
  • Spectrum, frequency, severity and management of other side effects, such as peripheral neuropathy, pneumonitis and gastrointestinal toxicities, in patients receiving mirvetuximab soravtansine

Register Today

ISS VIII: A Treatment Option for Patients with Primary Advanced or Recurrent Endometrial Cancer

Supporting company: GSK

Sunday, March 16 | 12:30 – 2:00 p.m. PT | Room 6E

Faculty: Thomas C. Krivak, MD   

Learn about the efficacy and safety data of JEMPERLI in combination with carboplatin and paclitaxel followed by JEMPERLI as a single agent for primary advanced or recurrent endometrial cancer from the RUBY Part 1 trial. 

 

ISS IX: Advancing Care in Recurrent Low-Grade Serous Ovarian Cancer: A Case Based Approach

Supporting company: Verastem

Monday, March 17 | 7:00 – 8:15 a.m. PT | Room 6AB

Moderator: Brian Slomovitz, MD, FACOG

Faculty: Isabelle Ray-Coquard, MD, PhD; Rachel N. Grisham, MD; and David Gershenson, MD

This session will explore the evolving treatment landscape of frontline and recurrent low-grade serous ovarian cancer (LGSOC), with primary focus on recurrent LGSOC, a distinct subtype of ovarian cancer that presents challenges in clinical management. The session will provide attendees with expert insights into recent clinical data, focusing on innovative therapies, combination treatment regimens, and emerging clinical trial results. By expanding the treatment options and improving therapeutic outcomes, we aim to maximize patient survival and quality of life. Attendees will gain a deeper understanding of current and future treatment strategies, with an emphasis on making informed decisions that can lead to more personalized care for patients with recurrent LGSOC.

ISS X: A Treatment Option for Patients with a Certain Type of Advanced Cervical Cancer

Supporting company: Merck

Monday, March 17 | 7:00-8:15 a.m. PT | Room 6E

Faculty: Thomas C. Krivak, MD

  • Review clinical data supporting a treatment option for patients with a certain type of advanced cervical cancer
  • Review a case study of a hypothetical patient with a certain type of advanced cervical cancer

ISS XI: Navigating the Evolving Landscape of Endometrial Cancer

Supporting company: Karyopharm

Monday, March 17 | 12:00-1:30 p.m. PT | Room 6AB

Moderator: Kathleen Moore, MD

Faculty: Linda Duska, MD and Scott Jordan, MD 

This ninety-minute symposium will address the evolving landscape of endometrial cancer treatment, with a particular focus on an XPO1 inhibitor endometrial cancer program. As treatment strategies for advanced endometrial cancer continue to evolve, this session will explore the currently enrolling Phase 3 trial evaluating selinexor maintenance therapy in patients with TP53 wild-type (WT) advanced/recurrent endometrial cancer.

Additionally, the latest clinical trial data will be reviewed, along with practical case studies on patients that may be eligible for the XPORT-042 study.  By the end of the session, participants will have a deeper understanding of the unmet needs in advanced endometrial cancer and the XPO1 inhibitor endometrial program, with practical insights on potentially eligible patients.

 

ISS XII: Patient and Provider Perspectives on Overcoming Healthcare  Disparities in Gynecologic Cancers

Supporting Company: GSK Medical

Monday, March 17 | 12:00 p.m. – 1:30 p.m. | Room 606-609

Faculty: Bhavana Pothuri MD, MS and John Farley, MD, FACOG, FACS 

In this non-promotional medical symposium, a panel will discuss barriers to equitable care in gynecological cancers, analyze obstacles in management and review strategies to address healthcase disparities.  In addition, the symposium will include a discussion around patient preferences and the importance of shared decision making.